News & Updates

P2B001, an investigational drug formulation that combines extended release (ER) doses of pramipexole and rasagiline, shows promise in managing Parkinson’s Disease (PD), conferring symptom control similar to that achieved with the marketed ER pramipexole while reducing the troublesome side effect of excessive daytime sleepiness.

Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.

Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.

Use of vitamin D but not calcium supplementation appears effective at preventing multiple sclerosis (MS) in individuals of European descent, suggests a recent study.

A recent study has shown that antipsychotic monotherapy does not reduce the risk of hospitalization for severe physical health problems when compared with polypharmacy in patients with schizophrenia.

A meta-analysis of randomized trials has revealed that influenza vaccination is effective at preventing all-cause mortality, cardiovascular mortality, major acute cardiovascular events, and acute coronary syndrome (ACS) among patients with coronary artery disease (CAD), particularly in those with ACS.